In the dyslipidemia treatment market, a combination of Statin + Ezetimibe is gaining explosive popularity. The annual prescription market has more than quadrupled over the past five years, exceeding 600 billion won. Rosuvastatin +Ezetimibe is leading the market growth.
According to UBIST, a pharmaceutical research institute, the amount of outpatient prescriptions for Statin +Ezetimibe was 609.9 billion won, up 23.1% from the previous year. It increased 52.3% in two years from 40.4 billion won in 2019. It showed rapid growth every year from 136.9 billion won in 2016 to 345.4% in five years.

Sales of Rosuvastatin and Ezetimibe are forming the largest market. Last year, the prescription amount of Rosu